

Caring for Carcinoid Foundation

E-Update: Number 12, 2006

In this issue:

Events

- Team Caring for Carcinoid Foundation in 2006 Pan-Mass Challenge - Boston, MA (photos)
- 2nd Annual Run for Hope - Fort Collins, CO (photos)
- Team Caring for Carcinoid Foundation in 2006 Jimmy Fund Walk - Boston, MA (upcoming)

Foundation

- CFCF E-Updates Reach the Worldwide Carcinoid Community

Website

- CFCF Launches "What is...?" to Provide Information on Cutting-Edge Carcinoid Research
- CFCF Launches Photo Gallery
- CFCF Launches E-Updates Archive

Research

- CFCF Recognized in *Journal of Clinical Oncology*

Events

Team Caring for Carcinoid Foundation in 2006 Pan-Mass Challenge - Boston, MA (photos)

[Team Caring for Carcinoid Foundation](#) completed a highly successful Pan-Mass Challenge on August 5-6, 2006. 43 cyclists rode with the team and raised over \$120,000. 100% of every dollar received by the Caring for Carcinoid Foundation funds carcinoid and neuroendocrine research.

The Caring for Carcinoid Foundation is grateful to:

- [Anne Doyle](#) - Team captain who led this extraordinary effort and rode in honor of her dad, [Hugh Doyle](#).
- [Don Alden](#) - Team member from Alden Marketing Group who designed the cycling jerseys and socks.
- [Kirkpatrick & Lockhart Nicholson Graham LLP](#) - Team sponsor who funded the cycling jerseys and socks.
- [All the team members](#) - Their hard work and dedication will have a significant impact on carcinoid and neuroendocrine research.

[Read article in *Lincoln Journal*](#)

[View photos](#)

2nd Annual Run for Hope - Fort Collins, CO (photos)

The 2nd annual [Run for Hope](#) took place on August 12, 2006 in Fort Collins, Colorado. This event was organized by Jeanne Lambert with her family and friends. Once again, the Run for Hope proved a major success due to the tireless efforts of Jeanne and many volunteers.

In addition, Jeanne succeeded in having August proclaimed "Carcinoid Cancer Awareness Month" by the State of Colorado and City of Fort Collins. An excerpt from the Fort Collins proclamation:

"Whereas, the Second Annual Run for Hope 5K will be held on August 12, 2006 to raise support for the Caring for Carcinoid Foundation and the Poudre Valley Cancer Treatment and Research Center;

Now, therefore, I, Doug Hutchinson, Mayor of Fort Collins, do hereby proclaim August 2006 as Carcinoid Cancer Awareness Month and encourage the citizens of Fort Collins to become aware of this devastating disease and to participate in support for research to find a cure."

[See race results](#)

[Read proclamation of "Carcinoid Awareness Month"](#)

[Read article in *The Coloradoan*](#)

[View photos](#)

Team Caring for Carcinoid Foundation in 2006 Jimmy Fund Walk - Boston, MA (upcoming)

[Team Caring for Carcinoid Foundation](#) will participate in the Jimmy Fund Walk on September 17, 2006. Be active, join Team Caring for Carcinoid Foundation, and walk along the course of the famous Boston Marathon to help fight carcinoid. 100% of every dollar received by the Caring for Carcinoid Foundation funds carcinoid and neuroendocrine research.

There are three Walk routes of varying distances:

- 26.2 miles: Full marathon distance
- 13.1 miles: Half marathon distance
- 3 miles: Make a big difference in a short distance

The Jimmy Fund Walk is one of the nation's leading fundraising events. Since 1989, it has raised more than \$40 million. The Jimmy Fund Walk is organized by Dana-Farber Cancer Institute with the following mission:

"Most of us know someone affected by cancer and are passionate about the mission of protecting our friends and loved ones from all forms of the disease. By walking and raising money for research and patient care at Dana-Farber Cancer Institute, you can make a monumental difference for families battling cancer.

The Boston Marathon Jimmy Fund Walk is an event focused on raising critical funds to support

cutting-edge research and compassionate patient care at Dana-Farber. No one has to face this disease alone. You can help."

To join: Click "Join Our Team" on [Team Caring for Carcinoid Foundation website](#)

For questions: E-mail info@caringforcarcinoid.org

Foundation

CFCF E-Updates Reach the Worldwide Carcinoid Community

The Caring for Carcinoid Foundation E-Updates now reach the worldwide carcinoid community. Our E-Updates reach subscribers in 42 U.S. states and 12 countries.

Please help us reach more carcinoid patients, families, and friends. Just pass along our link for free E-Updates so that new subscribers can also benefit from the latest information on new carcinoid treatments and breakthrough carcinoid research. No one should feel alone in our fight against carcinoid, regardless of where they live.

[View map of CFCF worldwide coverage](#)

[Link for free E-Updates](#)

Website

CFCF Launches "What is...?" to Provide Information on Cutting-Edge Carcinoid Research

The Caring for Carcinoid Foundation launched ["What is...?"](#) to provide information on cutting-edge carcinoid research.

We believe it is critical to inform carcinoid patients, family, and friends about cutting-edge carcinoid research because it will take a team effort to cure carcinoid.

Everyone in the carcinoid community can help discover a cure for carcinoid. One way is to stay informed about the latest advances in carcinoid research and share this knowledge with:

- Doctors
- Nurses
- Journalists
- Public officials
- All who will join our fight against carcinoid

The key is to raise awareness about carcinoid and the cutting-edge research we are pursuing to discover a cure. By reading "What is...?" regularly and sharing your knowledge, you will stay well informed and contribute to the fight against carcinoid.

To start, our topics are the following:

- [What is a mouse model?](#)
 - [Why critical to cancer research](#)
 - [Role in carcinoid research](#)
- [What is a cell line?](#)
 - [Why critical to cancer research](#)
 - [Role in carcinoid research](#)
- [What is proteomics?](#)
 - [Why critical to cancer research](#)
 - [Role in carcinoid research](#)

CFCF Launches Photo Gallery

The Caring for Carcinoid Foundation launched a [photo gallery](#) to share smiles, laughter, and hope with patients, families, and friends in the carcinoid community.

Enjoy viewing all the pictures from our recent events:

- [2nd Annual Run for Hope](#)
- [2006 Pan-Mass Challenge](#)
- [Research Planning](#)
- [NECC - 2006 Conference](#)
- [Massachusetts General Hospital - "The HapMap"](#)
- [CCTS - "Living with Carcinoid, Living with Hope!"](#)
- [SEA4Carcinoid - "Celebrate Life!"](#)

CFCF Launches E-Updates Archive

The Caring for Carcinoid Foundation launched an [E-Updates archive](#) on our website.

Over the past 18 months, we have circulated 18 E-Updates. These free E-Updates provide the latest information on new carcinoid treatments and breakthrough carcinoid research. If you missed any E-Updates, please visit the archive.

Research

CFCF Recognized in *Journal of Clinical Oncology*

An article entitled, "Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors" appeared in the peer-reviewed journal, *Journal of Clinical Oncology*. This article recognizes the Caring for Carcinoid Foundation for its research funding support.

The authors are [Matthew H. Kulke](#), Emily K. Bergsland, David P. Ryan, Peter C. Enzinger, [Thomas J. Lynch](#), Andrew X. Zhu, Jeffrey A. Meyerhardt, John V. Heymach, William E. Fogler, Carolyn Sidor, Ann Michelini, Kate Kinsella, Alan P. Venook, and Charles S. Fuchs. These authors conclude:

"Endostatin is a 20-kd proteolytic fragment of collagen XVIII that, in preclinical studies, has been

shown to have antiangiogenic and antitumor activity. Both preclinical and human phase I studies of recombinant human endostatin (rhEndostatin) suggested activity in neuroendocrine tumors, which are known to be hypervascular. We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors.

... rhEndostatin was associated with minimal toxicity. However, among 40 patients assessable for radiologic response, none experienced partial response to therapy, as defined by WHO criteria. The median steady-state trough level achieved after dose escalation was 331 ng/mL, within the postulated therapeutic range.

Treatment with rhEndostatin did not result in significant tumor regression in patients with advanced neuroendocrine tumors."

[Read *Journal of Clinical Oncology* article](#)

Links to CFCF Website

- [CFCF Frequently Asked Questions](#)
- [CFCF Donors](#)
- [CFCF Home Page](#)